STOCKHOLM, Sept. 14, 2026 /PRNewswire/ -- The Board of Directors of SciBase Holding AB (publ) ("SciBase" or the "Company") is publishing an information document in connection with the rights issue of shares of approximately SEK 58 million (the "Rights Issue"), which the Company's Board of Directors resolved upon on 3 September 2026. The information document is available on the Company's website and will also be available on Bergs Securities AB's ("Bergs Securities") website at https://www.bergssecurities.se/.

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUSES, REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED UNDER SWEDISH LAW, IS PROHIBITED OR WOULD OTHERWISE BE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION, OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH MEASURES. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE FOR FURTHER INFORMATION.

In connection with the Rights Issue, the Company has prepared an information document (the "Information Document"). The Information Document is not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017, on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended (the "Prospectus Regulation") and has not been approved or reviewed by any regulatory authority in any jurisdiction. Nor does the Information Document constitute an exemption document in the form prescribed in accordance with the requirements of Annex IX to Article 1(4)(db) of the Prospectus Regulation.

SciBase today announces that the Information Document has been published and is available on the Company's website, http://www.scibase.com/, and will also be available on Bergs Securities' website, https://www.bergssecurities.se/.

Subscription forms will be available on the Company's website and will also be available on Bergs Securities' website, https://www.bergssecurities.se/.

Indicative timetable for the Rights Issue


 Subscription period                                       15-29 September 2026



 Trading in paid subscribed shares (BTA)                   15 September -16 October
                                                             2026



 Expected publication of the outcome of the Rights Issue 
 1 October 2026

Advisers

SciBase has engaged Bergs Securities and Birchtree Advisory as financial advisers and BAHR as legal adviser in connection with the Rights Issue. Bergs Securities is also acting as issuing agent in connection with the Rights Issue.

For further information, please contact:

Jesper Høiland, Chairman of the Board, telephone +45 612 207 30
Michael Colérus, Chief Financial Officer, telephone +46 70 341 34 72

Certified Adviser (CA):

DNB Carnegie Investment Bank AB (publ)
Telephone: +46 8 588 68 570,
E-mail: certifiedadviser@carnegie.se

About SciBase:

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases

Important information:

The publication, release or distribution of this press release may in certain jurisdictions be subject to restrictions by law, and persons in the jurisdictions in which this press release has been made public or distributed should inform themselves about, and comply with, such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with the applicable rules in each jurisdiction.

The availability of the Rights Issue to holders not resident in Sweden may be affected by the legislation of the relevant jurisdiction in which they are located. Holders not resident in Sweden should inform themselves about, and comply with, all applicable laws and regulations.

This press release does not constitute an offer of, or an invitation to, acquire or subscribe for any securities in SciBase in any jurisdiction, either from SciBase or from anyone else. This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared in connection with the Rights Issue. The Company has prepared and published an information document in respect of the Rights Issue. The information document is available on the Company's website (https://investors.scibase.se).

This press release does not identify, and does not purport to identify, any risks (direct or indirect) that may be associated with an investment in the Company. The information in this press release is intended only to describe the background to the Rights Issue and does not purport to be complete or exhaustive. No representation is made as to the accuracy or completeness of the information in this press release.

This press release does not constitute an offer of, or an invitation to, acquire or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended from time to time (the "Securities Act"), and may not be offered or sold in the United States absent registration, or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea or any other jurisdiction in which such release, publication or distribution of this information would be unlawful or where such action is subject to legal restrictions or would require registration, or measures other than those required under Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation.

Forward-looking statements

Matters discussed in this press release may contain forward-looking statements. Forward-looking statements are all statements that do not relate to historical facts and events, as well as statements relating to the future which, for example, contain expressions such as "anticipates", "intends", "may", "will", "should", "estimates", "believes", "could", "plans", "continues", "potential", "estimates", "forecasts", "known" or similar expressions. In particular, these statements relate to future results, financial position, cash flows, plans and expectations regarding the company's operations and management, future growth and profitability, as well as the general economic and regulatory environment and other circumstances affecting the company, many of which are in turn based on further assumptions, such as the absence of changes in existing political, legal, tax, market or economic conditions or in applicable laws (including, but not limited to, accounting principles, accounting methods and tax policies), which, individually or together, may be material to the company's results or its ability to conduct its operations. Although the Company considers that these assumptions were reasonable when they were made, they are by their nature subject to significant known and unknown risks, uncertainties, contingencies and other important factors that are difficult or impossible to predict and that may be beyond the Company's control. Such risks, uncertainties, contingencies and other material factors may cause actual events to differ materially from the expectations expressed or implied in such forward-looking statements. Prospective investors should therefore not place undue reliance on the forward-looking information contained herein, and prospective investors are strongly recommended to read those sections of the information document that contain a more detailed description of factors that may affect the Company's business and the market in which the Company operates. The information, opinions and forward-looking statements in this press release are valid only as at the date of this press release and may be subject to change without notice.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/scibase/r/scibase-publishes-information-document-regarding-the-rights-issue,c4395656

The following files are available for download:


 
 https://mb.cision.com/Main/12371/4395656/4267964.pdf PR (publication of information
                                                          document)

View original content:https://www.prnewswire.co.uk/news-releases/scibase-publishes-information-document-regarding-the-rights-issue-302877707.html

Tags

More Like This

SciBase publishes information document regarding rights issue

SCIBASE RESOLVES ON A RIGHTS ISSUE OF SHARES OF APPROXIMATELY SEK 58 MILLION

SciBase publishes prospectus in connection with upcoming rights issue

The Board of Directors of SciBase resolves on a previously communicated rights issue of shares of approximately SEK 83 million

SciBase resolves on a directed issue of approximately SEK 33 million and a rights issue of approximately SEK 15 million

Today is the first day of the subscription period in SciBase rights issue

SciBase announces outcome in rights issue of units

SciBase publishes prospectus